Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding$1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.

Health Diagnostics

Health Care

Biotechnology

Alzeca Biosciences

Alzeca Biosciences' headquarters in Houston, TX, United States

Alzeca Biosciences

Org chart

Teams

Scientific Advisory Team

Offices

Similar companies